Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation Therapy
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
PURPOSE: We characterize the consequences of androgen deprivation therapy on body composition in elderly men. MATERIALS AND METHODS: Using a dual energy x-ray absorptiometry instrument, we determined the changes in bone mineral density, bone mineral content, fat body mass and lean body mass in 35 patients with prostate cancer without bone metastases who received luteinizing hormone releasing hormone analogue for 12 months. RESULTS: At baseline conditions 46% of cases were classified as osteopenic and 14% as osteoporotic at the lumbar spine and 40% were osteopenic and 4% osteoporotic at the hip. Androgen deprivation significantly decreased bone mineral density either at the lumbar spine (mean gm./cm.2 [SD] 1.00 [0.194], 0.986 [0.172] and 0.977 [0.182] at baseline, and 6 and 12 months, respectively, p <0.002) or the hip (0.929 [0.136], 0.926 [0.144] and 0.923 [0.138], p <0.03). A more than 2% decrease in bone mineral density was found at the lumbar spine in 19 men (54.3%) and at the hip in 15 (42.9%). Bone mineral content paralleled the bone mineral density pattern. Lean body mass decreased (mean gm. [SD] 50,287 [6,656], 49,296 [6,554] and 49,327 [6,345], p <0.003), whereas fat body mass consistently increased (18,115 [6,209], 20,724 [6,029] and 21,604 [5,923] p <0.001). CONCLUSIONS: Serial bone densitometry evaluation during androgen deprivation therapy may allow the detection of patients with prostate cancer at risk for osteoporotic fractures, that is those with osteopenia or osteoporosis at baseline and fast bone loss. The change in body composition may predispose patients to accidental falls, thus increasing the risk of bone fracture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Statistical Methods
(1999) · Technometrics · doi:10.1080/00401706.1999.10485954 · Cited by 6,090
Partin, A. W. (1997) · JAMA · doi:10.1001/jama.277.18.1445 · Cited by 1,794
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Alendronate for the Treatment of Osteoporosis in Men
Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 973
Risk Factors for Longitudinal Bone Loss in Elderly Men and Women: The Framingham Osteoporosis Study
Hannan, M. T., Felson, D. T., Dawson-Hughes, B., Tucker, K. L., Cupples, L. A., Wilson, P. W. F., & Kiel, D. P. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.710 · Cited by 775
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 696
Smith, J. C., Bennett, S., Evans, L. M., Kynaston, H. G., Parmar, M., Mason, M. D., Cockcroft, J. R., Scanlon, M. F., & Davies, J. S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7851 · Cited by 458
PROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
DANIELL, H. W., DUNN, S. R., FERGUSON, D. W., LOMAS, G., NIAZI, Z., & STRATTE, P. T. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)68000-7 · Cited by 452
ŠTĚPÁN, J. J., LACHMAN, M., ZVĚŘINA, J., PACOVSKÝ, V., & BAYLINK, D. J. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-523 · Cited by 424
Mauras, N., Hayes, V., Welch, S., Rini, A., Helgeson, K., Dokler, M., Veldhuis, J. D., & Urban, R. J. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4892 · Cited by 368
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Androgen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083
Pilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., Hug, E. B., Asbell, S. O., & Grignon, D. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.08.047 · Cited by 913
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831
Vanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., & Ohlsson, C. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0003 · Cited by 717
Review of Exercise Intervention Studies in Cancer Patients
Galvão, D. A., & Newton, R. U. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.085 · Cited by 578
Insulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer
Greenspan, S. L., Coates, P., Sereika, S. M., Nelson, J. B., Trump, D. L., & Resnick, N. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0183 · Cited by 411
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., & Zakai, N. (2010) · Circulation · doi:10.1161/circulationaha.109.192695 · Cited by 383
Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Saylor, P. J., & Smith, M. R. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.01.047 · Cited by 349
Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes
Alibhai, S. M. H., Duong-Hua, M., Sutradhar, R., Fleshner, N. E., Warde, P., Cheung, A. M., & Paszat, L. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0923 · Cited by 334
Sadovsky, R., Basson, R., Krychman, M., Morales, A. M., Schover, L., Wang, R., & Incrocci, L. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01620.x · Cited by 310
Meier, C. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.2 · Cited by 274
“The median (range) serum testosterone level for quartile 1 was 227 (3-291) ng/dL; for quartile 2, 343 (294-398) ng/dL; for quartile 3, 473 (401-559) ng/dL; and for quartile 4, 646 (559-1519) ng/dL.”
BackgroundChanges in fat and lean body mass during androgen-deprivation therapy for prostate cancer
Smith, M. R. (2004) · Urology · doi:10.1016/j.urology.2003.10.063 · Cited by 259
Diamond, T. H., Higano, C. S., Smith, M. R., Guise, T. A., & Singer, F. R. (2004) · Cancer · doi:10.1002/cncr.20056 · Cited by 255
Bone Loss and Fracture Risk Associated with Cancer Therapy
Guise, T. A. (2006) · The Oncologist · doi:10.1634/theoncologist.11-10-1121 · Cited by 239
“Similarly, bone loss commonly occurs in men with prostate cancer who are treated with ADT, with annual BMD declines of 2%–8% [23, 24 ].”
BackgroundManagement of Complications of Prostate Cancer Treatment
Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., & Smith, M. R. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0002 · Cited by 196
Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., Saad, F., Egerdie, B., Sieber, P. R., Tammela, T. L. J., Ke, C., Leder, B. Z., & Goessl, C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8850 · Cited by 196
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., Zakai, N., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20061 · Cited by 188
Smith, M. R., Goode, M., Zietman, A. L., McGovern, F. J., Lee, H., & Finkelstein, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.174 · Cited by 188
Morote, J., Morin, J. P., Orsola, A., Abascal, J. M., Salvador, C., Trilla, E., Raventos, C. X., Cecchini, L., Encabo, G., & Reventos, J. (2007) · Urology · doi:10.1016/j.urology.2006.11.002 · Cited by 184
Alibhai, S. M. H., Gogov, S., & Allibhai, Z. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.06.006 · Cited by 173
“Although we have discussed the major adverse health ffects of ADT, other changes have been described, including hanges in body fat content and fat distribution [131–134], in l s v r ology/Hematology 60 (2006) 201–215 211”
BackgroundDissection of genetic variation and evidence for pleiotropy in male pattern baldness
Yap, C. X., Sidorenko, J., Wu, Y., Kemper, K. E., Yang, J., Wray, N. R., Robinson, M. R., & Visscher, P. M. (2018) · Nature Communications · doi:10.1038/s41467-018-07862-y · Cited by 124
Boxer, R. S., Kenny, A. M., Dowsett, R., & Taxel, P. (2005) · The Aging Male · doi:10.1080/13685530500361226 · Cited by 81
“Few studies have determined the longitudinal changes in skeletal muscle mass or lean tissue mass in men with PCa treated with LHRH-A and the studies lack control groups [16,17,18].”
BackgroundStorer, T. W., Miciek, R., & Travison, T. G. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.104 · Cited by 70
Darwish-Yassine, M., Berenji, M., Wing, D., Copeland, G., Demers, R. Y., Garlinghouse, C., Fagerlin, A., Newth, G. E., Northouse, L., Holmes-Rovner, M., et al. (2014) · Journal of Cancer Survivorship · doi:10.1007/s11764-013-0312-8 · Cited by 55
Metadata
- Authors
- BERRUTI, A., DOGLIOTTI, L., TERRONE, C., CERUTTI, S., ISAIA, G., TARABUZZI, R., REIMONDO, G., MARI, M., ARDISSONE, P., DE LUCA, S., FASOLIS, G., FONTANA, D., ROCCA ROSSETTI, S., ANGELI, A., & PIEMONTESE, F. T. G. O. U. P. (. O. U. P. ). R. O.
- Venue
- Journal of Urology
- Published
- 2002-06
- Volume
- 167
- Issue
- 6
- Pages
- 2361-2367
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W1980224053
- Cited by
- 315
- References
- 28
- FWCI
- 15.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.